# Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

> **NCT04073290** · PHASE4 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 238 (estimated)

## Conditions studied

- Hepatic Encephalopathy
- Cirrhosis, Liver
- Portal Hypertension
- Liver Diseases
- Pathological Processes

## Interventions

- **DRUG:** Rifaximin 550 milligram Oral Tablet [XIFAXAN]
- **DRUG:** Placebo oral tablet
- **DRUG:** Lactulose 667 milligram/milliliter Oral Solution

## Key facts

- **NCT ID:** NCT04073290
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-21
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073290, "Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04073290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*